Literature DB >> 25293772

Brentuximab vedotin.

Stephen M Ansell1.   

Abstract

Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30(+) malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.
© 2014 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25293772     DOI： 10.1182/blood-2014-06-537514

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  26 in total

Review 1.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

2.  Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.

Authors:  Yusuke Koizumi; Tomoko Uehira; Yasunori Ota; Yoshihiko Ogawa; Keishiro Yajima; Junko Tanuma; Mihoko Yotsumoto; Shotaro Hagiwara; Satoshi Ikegaya; Dai Watanabe; Hitoshi Minamiguchi; Keiko Hodohara; Kenta Murotani; Hiroshige Mikamo; Hideho Wada; Atsushi Ajisawa; Takuma Shirasaka; Hirokazu Nagai; Yoshinori Kodama; Tsunekazu Hishima; Makoto Mochizuki; Harutaka Katano; Seiji Okada
Journal:  Int J Hematol       Date:  2016-09-07       Impact factor: 2.490

3.  Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome.

Authors:  Mohammad H Abu Arja; Suzanne E Conley; Violeta Salceda; Fahd Al-Sufiani; Daniel R Boué; Jonathan L Finlay
Journal:  Childs Nerv Syst       Date:  2017-12-13       Impact factor: 1.475

4.  Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).

Authors:  Aman P Singh; Dhaval K Shah
Journal:  AAPS J       Date:  2017-04-03       Impact factor: 4.009

Review 5.  Antibody-drug conjugates for cancer therapy.

Authors:  Anish Thomas; Beverly A Teicher; Raffit Hassan
Journal:  Lancet Oncol       Date:  2016-06       Impact factor: 41.316

Review 6.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 7.  Peripheral T-cell lymphoma - are we making progress?

Authors:  Niloufer Khan; Neval Ozkaya; Alison Moskowitz; Ahmet Dogan; Steven Horwitz
Journal:  Best Pract Res Clin Haematol       Date:  2018-07-17       Impact factor: 3.020

8.  Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Authors:  Katharina Blatt; Sabine Cerny-Reiterer; Juliana Schwaab; Karl Sotlar; Gregor Eisenwort; Gabriele Stefanzl; Gregor Hoermann; Matthias Mayerhofer; Mathias Schneeweiss; Sylvia Knapp; Thomas Rülicke; Emir Hadzijusufovic; Karin Bauer; Dubravka Smiljkovic; Michael Willmann; Andreas Reiter; Hans-Peter Horny; Peter Valent
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

Review 9.  Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.

Authors:  Jonathan Hebb; Holbrook Kohrt
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 4.213

10.  Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan.

Authors:  Hsiao-Wen Kao; Tung-Liang Lin; Lee-Yung Shih; Po Dunn; Ming-Chung Kuo; Yu-Shin Hung; Jin-Hou Wu; Tzung-Chih Tang; Hung Chang; Tseng-Tong Kuo; Che-Wei Ou; Po-Nan Wang
Journal:  Int J Hematol       Date:  2016-04-19       Impact factor: 2.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.